Incidence and Outcomes of COVID-19 Vaccine Hypersensitivity Reactions and Success of COVID-19 Vaccine Provocation Tests Post Previous COVID-19 Vaccine Hypersensitivity

Author:

Kurniawan Adi1ORCID,Koesnoe Sukamto2,Yunihastuti Evy2ORCID,Shatri Hamzah3ORCID

Affiliation:

1. Allergy and Immunology Subspecialty Education Programs, Department of Internal Medicine, Faculty of Medicine, University of Indonesia, Jakarta 10430, Indonesia

2. Division of Allergy and Immunology, Department of Internal Medicine, Faculty of Medicine, University of Indonesia/Cipto Mangunkusumo Hospital, Jakarta 10430, Indonesia

3. Division of Pyschosomatic and Palliative, Department of Internal Medicine, Faculty of Medicine, University of Indonesia/Cipto Mangunkusumo Hospital, Jakarta 10430, Indonesia

Abstract

Background: The COVID-19 pandemic has led to high mortality rates. There have been reports of hypersensitivity reactions with mild to severe symptoms. The COVID-19 vaccine provocation test is a vaccination protocol for individuals with a history of hypersensitivity. This study aims to determine the benefits of COVID-19 vaccine provocation tests in patients with a history of hypersensitivity reactions to COVID-19 vaccines and its influencing factors. Objective: To determine the incidence, severity, outcome of hypersensitivity reactions, and success of the COVID-19 vaccine provocation test. Methods: A retrospective cohort study was conducted, using subjects taken from medical record data at the RSCM who had received COVID-19 vaccination with a history of hypersensitivity. Data was taken from the COVID-19 vaccination records at the RSCM, BPJS Health Primary Care application. Results: From a total of 29,036 doses of the COVID-19 vaccine, 44 patients experienced hypersensitivity reactions. As many as 38.64% did not continue vaccination, 2.27% experienced mild hypersensitivity, and 59.44% were successfully vaccinated. Conclusions: People with a history of hypersensitivity reactions to COVID-19 vaccines can still receive subsequent COVID-19 vaccinations at healthcare facilities equipped with anaphylaxis kits and immunology allergists.

Publisher

MDPI AG

Reference18 articles.

1. Protocol of safe vaccination against COVID-19 in patients with high risk of allergic reactions;Romantowski;Clin. Transl. Allergy,2022

2. Kemenkes, R.I. (2023, April 23). Cakupan Vaksinasi COVID-19 di Indonesia. Available online: https://layanandata.kemkes.go.id/katalog-data/covid-19/ketersediaan-data/vaksinasi-covid-19.

3. Amarasinghe, A., World Health Organization, and Global Advisory Committee on Vaccine Safety (2014). Global Manual on Surveillance of Adverse Events Following Immunization, World Health Organization.

4. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine;Baden;N. Engl. J. Med.,2021

5. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine;Polack;N. Engl. J. Med.,2020

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3